Company: PTHS
Filing Date: 2025-09-16
Form Type: 8-K/A
Source: 0001753926-25-001500
Chunk: 86

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-09-16
Form: 8-K/A
Chunk 86
---
1)(2)       |     |  54 |     | Director                                        |

| (1) | Member of the audit                 
 committee.                          |
| (2) | Member of the compensation          
 committee.                          |
| (3) | Member of the nominating            
 and corporate governance committee. |

Executive Officers

Scott M. Pleshahas served as LNHC’s Chief Executive Officer since November 2023 and as our Chief Executive Officer
since July 2025. Prior to joining LNHC, Mr. Plesha served as the President and Chief Commercial Officer at BioDelivery Sciences
(BDSI), a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, from January 2018
until it was acquired by Collegium Pharmaceutical in 2022. Mr. Plesha joined BioDelivery Sciences in August 2015 as Senior
Vice President, Sales, and assumed the additional responsibility of leading the marketing department in December 2015. He
previously served as Senior Vice President of Gastrointestinal Sales at Salix Pharmaceuticals. Before Salix, Mr. Plesha was
a Regional Sales Manager for Oclassen Dermatologics, a division of Watson Laboratories, and in commercial roles of increasing responsibility
at Solvay Pharmaceuticals. Mr. Plesha received a Bachelor of Arts in Pre-Medical Studies from DePauw University. He was selected
to serve as the Combined Company’s Chief Executive Officer, President and Director due to his previous leadership of LNHC
and extensive experience in sales and sales management in the pharmaceutical and medical industries.

Francis Knuettel IIhas served as Channel’s Chief Financial Officer, Treasurer and Secretary since June 2022,
as Channel’s Chief Executive Officer from July 2023 through July 2025, and served as a member of the Channel board of directors
from August 2024 through July 2025. Prior to that, from December 2020 to April 2022, he served as Chief Executive
Officer and director of Unrivaled Brands, where he helped grow revenue from an annualized rate of $10 million to $100 million
in six quarters by acquiring three companies in the sector. He also served as Chief Financial Officer of OCG, Inc. from June 2019
to January 2021 and held various roles at MJardin Group, including Chief Strategy Officer, from August 2018 to January 2019.
Prior to MJardin Group, Mr. Knuettel served as